Functional characterization of transforming growth factor β type II receptor mutants in human cancer

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1986-1992

  De, Malabika ^a   Yan, Wu ^a   De Jonge, Rosalein R ^a   Garrigue Antar, Laure ^a   Vellucci, Vincent F ^a   Reiss, Michael ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CLONING, MOLECULAR; FIBRONECTINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEAD AND NECK NEOPLASMS; HUMANS; KERATINOCYTES; MUTAGENESIS, SITE-DIRECTED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0032080855     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Thompson, A. M., Kerr, D. J., and Steel, C. M. Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br. J. Cancer, 63: 609-614, 1991.
2. Rifkin, D. B., Kojima, S., Abe, M., and Harpel, J. G. TGF-β. Structure, function, and formation. Thromb. Haemostasis, 70: 177-179, 1993.
3. Flaumenhaft, R., and Rifkin, D. B. The extracellular regulation of growth factor action. Mol. Cell. Biol., 3: 1057-1065, 1992.
4. Border, W. A., and Noble, N. A. Transforming growth factor β in tissue fibrosis. N. Engl. J. Med., 331: 1286-1292, 1994.
5. Reiss, M., and Dibble, C. L. Reinitiation of DNA synthesis in quiescent mouse keratinocytes: regulation by polypeptide hormones, cholera toxin, dexamethasone, and retinoic acid. In Vitro (Rockville), 24: 537-544, 1988.
6. Ichijo, H., Momose, F., and Miyazono, K. Biological effects and binding properties of transforming growth factor-β on human oral squamous carcinoma cells. Exp. Cell Res., 187: 263-269, 1990.
7. Reiss, M., and Stash, E. B. High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor-β. Cancer Commun., 2: 363-369, 1990.
8. Fynan, T. M., and Reiss, M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncog., 4: 493-540, 1993.
9. Reiss, M. Transforming growth factor-β and cancer. A love-hate relationship? Oncol. Res., in press, 1998.
10. Massagué, J. TGF-β signaling: receptors, transducers, and MAD proteins. Cell, 85: 947-950, 1996.
11. Derynck, R., and Zhang, Y. Intracellular signaling: the Mad way to do it. Curr. Biol., 6: 1226-1229, 1996.
12. Macias-Silva, M., Abdollah, S., Hoodless, P. A., Pirone, R., Attisano, L., and Wrana, J. L. MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell, 87: 1215-1224, 1996.
13. Chen, Y., Lebrun, J. J., and Vale, W. Regulation of transforming growth factor β-and activin-induced transcription by mammalian Mad proteins. Proc. Natl. Acad. Sci. USA, 93: 12992-12997, 1996.
14. Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massagué, J. Partnership between DPC4 and SMAD proteins in TGF-β signaling pathways. Nature (Lond.), 383: 832-836, 1996.
15. Chen, X., Rubock, M. J., and Whitman, M. A transcriptional partner for MAD proteins in TGFβ signaling. Nature (Lond.), 383: 691-696, 1996.
16. de Winter, J. P., Roelen, B. A., ten Dijke, P., van der Burg, B., and van den Eijnden-van Raaij, A. J. DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene, 14: 1891-1899, 1997.
17. Hata, A., Lo, R. S., Wotton, D., Lagna, G., and Massagué, J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature (Lond.), 388: 82-87, 1997.
18. Shi, Y., Hata, A., Lo, R. S., Massagué, J., and Pavletich, N. P. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature (Lond.), 388: 87-93, 1997.
19. Kim, J., Johnson, K., Chen, H. J., Carroll, S., and Laughon, A. Drosophila Mad binds to DNA and directly mediates activation of vestigial by decapentaplegic. Nature (Lond.), 388: 304-308, 1997.
20. Chen, X., Weisberg, E., Fridmacher, V., Watanabe, M., Naco, G., and Whitman, M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature (Lond.), 389: 85-89, 1997.
21. kip1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
22. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
23. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
24. Reynisdottir, I., Polyak, K., Iavarone, A., and Massagué, J. Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev., 9: 1831-1845, 1995.
25. Ewen, M. E., Sluss, H. K., Whitehouse, L. L., and Livingston, D. M. TGFβ inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell, 74: 1009-1020, 1993.
26. 1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. USA, 90: 10315-10319, 1993.
27. Iavarone, A., and Massagué, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature (Lond.), 387: 417-422, 1997.
28. Roberts, A. B., Heine, U. I., Flanders, K. C., and Sporn, M. B. Transforming growth factor-β. Major role in regulation of extracellular matrix. Ann. N. Y. Acad. Sci., 580: 225-232, 1990.
29. Garrigue-Antar, L., Munoz-Antonia, T., Antonia, S. J., Gesmonde, J., Vellucci, V. F., and Reiss, M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res., 55: 3982-3987, 1995.
30. Knaus, P. I., Lindemann, D., DeCoteau, J. F., Perlman, R., Yankelev, H., Hille, M., Kadin, M. E., and Lodish, H. F. A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol. Cell. Biol., 16: 3480-3489, 1996.
31. Lu, S., Zhang, W., Akiyama, Y., Nomizu, T., and Yuasa, Y. Genomic structure of the transforming growth factor β type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res., 56: 4595-4598, 1996.
32. Takenoshita, S., Tani, M., Nagashima, M., Hagiwara, K., Bennett, W. P., Yokota, J., and Harris, C. C. Mutation analysis of coding sequences of the entire transforming growth factor β type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene, 14: 1255-1258, 1997.
33. Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L-C., Bapat, B., Gallinger, S., Andrulis, I., Thomsen, G. H., Wrana, J. L., and Attisano, L. MADR2 maps to 18q21 and encodes a TGF-β MAD-related protein that is functionally mutated in colorectal carcinoma, Cell, 86: 543-552, 1996.
34. Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Washington DC), 271: 350-353, 1996.
35. Arai, T., Akiyama, Y., Okabe, S., Ando, M., Endo, M., and Yuasa, Y. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. Cancer Lett., in press, 1998.
36. Lu, S-L., Akiyama, Y., Nagasaki, H., Saitoh, K., and Yuasa, Y. Mutations of the transforming growth factor-β type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun., 216: 452-457, 1995.
37. Hanks, S. K., and Quinn, A. M. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol., 200: 38-81, 1991.
38. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
39. Reiss, M., Pitman, S. W., and Sartorelli, A. C. Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans-retinoic acid. J. Natl. Cancer Inst., 74: 1015-1023, 1985.
40. Rangan, S. R. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer (Phila.), 29: 117-121, 1972.
41. Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., and Brenner, H. J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer, 15: 659-670, 1979.
42. Laiho, M., Weis, F. M. B., Boyd, F. T., Ignotz, R. A., and Massagué, J. Responsiveness to transforming growth factor-β (TGFβ) restored by complementation between cells defective in TGFβ receptors I and II. J. Biol. Chem., 266: 9108-9112, 1991.
43. Feng, X-H., Filvaroff, E. H., and Derynck, R. Transforming growth factor-β (TGFβ)-induced down-regulation of cyclin A expression requires a functional TGFβ receptor complex. J. Biol. Chem., 270: 24237-24245, 1995.
44. Lawler, S., Candia, A. F., Ebner, R., Shum, L., Lopez, A. R., Moses, H. L., Wright, C. V., and Derynck, R. The murine type II TGF-β receptor has a coincident embryonic expression and binding preference for TGF-β 1. Development (Camb.), 120: 165-175, 1994.
45. Kalkhoven, E., Roelen, B. A. J., de Winter, J. P., Mummery, C. L., van den Eijnden-van Raaij, A. J. M., van der Saag, P. T., and van der Burg, B. Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ., 6: 1151-1156, 1995.
46. Wrana, J. L., Attisano, L., Cárcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X-F., and Massagué, J. TGFβ signals through a heteromeric protein kinase receptor complex. Cell, 71: 1003-1014, 1992.
47. Reiss, M., Santoro, V., De Jonge, R. R., and Vellucci, V. F. Transfer of chromosome 18 into human head and neck squamous carcinoma cells: evidence for tumor suppression by Smad4/DPC4. Cell Growth Differ., 8: 407-415, 1997.
48. Geiser, A. G., Burmester, J. K., Webbink, R., Roberts, A. B., and Sporn, M. B. Inhibition of growth by transforming growth factor-β following fusion of two nonresponsive human carcinoma cell lines. J. Biol. Chem., 267: 2588-2593, 1992.
49. Sankar, S., Mahooti-Brooks, N., Bensen, L., McCarthy, T. L., Centrella, M., and Madri, J. A. Modulation of transforming growth factor β receptor levels on microvascular endothelial cells during in vitro angiogenesis. J. Clin. Invest., 97: 1436-1446, 1996.
50. 1 integrin receptor in malignancy. Invasion Metastasis, 14: 87-97, 1994.
51. Satterwhite, D. J., Aakre, M. E., Gorska, A. E., and Moses, H. L. Inhibition of cell growth by TGFβ1 is associated with inhibition of B-myb and cyclin A in both BALB/MK and Mv1Lu cells. Cell Growth Differ., 5: 789-799, 1994.
52. Ventura, F., Doody, J., Liu, F., Wrana, J. L., and Massagué, J. Reconstitution and transphosphorylation of TGF-β receptor complexes. EMBO J., 13: 5581-5589, 1994.
53. Chen, F., and Weinberg, R. A. Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor β receptor kinases. Proc. Natl. Acad. Sci. USA, 92: 1565-1569. 1995.
54. Vivien, D., Attisano, L., Wrana, J. L., and Massagué, J. Signaling activity of homologous and heterologous transforming growth factor-β receptor kinase complexes. J. Biol. Chem., 270: 7134-7141, 1995.
55. Feng, X. H., and Derynck, R. Ligand-independent activation of transforming growth factor (TGF) β signaling pathways by heteromeric cytoplasmic domains of TGF-β receptors. J. Biol. Chem., 271: 13123-13129, 1996.
56. Kalkhoven, E., Kwakkenbos-Isbrucker, L., Mummery, C. L., deLaat, S. W., van den Eijnden-van Raaij, A. J. M., van der Saag, P. T., and van der Burg, B. The role of TGF-β production in growth inhibition of breast tumor cells by progestins. Int. J. Cancer, 61: 80-86, 1995.
57. Rahimi, N., Tremblay, E., McAdam, L., Park, M., Schwall, R., and Elliott, B. Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ., 7: 263-270, 1996.
58. Chen, R-H., Ebner, R., and Derynck, R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGFβ activities. Science (Washington DC), 260: 1335-1338, 1993.
59. Wieser, R., Attisano, L., Wrana, J. L., and Massagué, J. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol. Cell. Biol., 13: 7239-7247, 1993.
60. Carcamo, J., Zentella, A., and Massagué, J. Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol. Cell. Biol., 15: 1573-1581, 1995.
61. Brand, T., and Schneider, M. D. Inactive type II and type I receptors for TGFβ are dominant inhibitors of TGFβ-dependent transcription. J. Biol. Chem., 270: 8274-8284, 1995.
62. Choi, M. E., and Ballerman, B. J. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-β receptors. J. Biol. Chem., 270: 21144-21150, 1995.
63. Yamamoto, H., Ueno, H., Ooshima, A., and Takeshita, A. Adenovirus-mediated transfer of a truncated transforming growth factor-β (TGFβ) type II receptor completely and specifically abolishes diverse signaling by TGFβ in vascular wall cells in primary culture. J. Biol. Chem., 271: 16253-16259, 1996.
64. Zhao, J., Bu, D., Lee, M., Slavkin, H. C., Hall, F. L., and Warburton, D. Abrogation of transforming growth factor-β type II receptor stimulates embryonic mouse lung branching morphogenesis in culture. Dev. Biol., 180: 242-257, 1996.
65. Fan, D., Chakrabarty, S., Seid, C., Bell, C. W., Schackert, H., Morikawa, K., and Fidler, I. J. Clonal stimulation of human colon carcinomas and human renal carcinomas mediated by TGFβ1. Cancer Commun., 1: 117-125, 1989.
66. Hsu, S., Huang, F., Hafez, M., Winawer, S., and Friedman, E. Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression. Cell Growth Differ., 5: 267-275, 1994.
67. Yan, Z. F., Winawer, S., and Friedman, E. Two different signal transduction pathways can be activated by transforming growth factor β1 in epithelial cells. J. Biol. Chem., 269: 13231-13237, 1994.
68. Taylor, S. S., Knighton, D. R., Zheng, J., Ten Eyck, L. F., and Sowadski, J. M. Structural framework for the protein kinase family. Annu. Rev. Cell Biol., 8: 429-462, 1992.
69. Zhang, F., Strand, A., Robbins, D., Cobb, M. H., and Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature (Lond.), 367: 704-711, 1994.
70. Luo, K., and Lodish, H. F. Positive and negative regulation of type II TGF-β receptor signal transduction by autophosphorylation on multiple serine residues. EMBO J., 16: 1970-1981, 1997.
71. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattain, M., and Willson, J. K. V. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
72. Lin, H. Y., Moustakas, A., Knaus, P., Wells, R. G., Henis, Y. I., and Lodish, H. F. The soluble exoplasmic domain of the type II transforming growth factor (TGFβ) receptor. J. Biol. Chem., 270: 2747-2754, 1995.
73. Wang, J., Sun, L., Myeroff, L., Wang, X., Gentry, L. E., Yang, J., Liang, J., Zborowska, E., Markowitz, S., Willson, J. K. V., and Brattain, M. G. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem., 270: 22044-22049, 1995.